Xeris Biopharma Holdings annual gross profit
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings Gross Profit Growth & History (XERS)
Xeris Biopharma Holdings's gross profit was $249.3M for fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $249.3M | $83.0M | +49.95% |
| 2024 | 2024-12-31 | $166.2M | $31.0M | +22.89% |
| 2023 | 2023-12-31 | $135.3M | $47.7M | +54.39% |
| 2022 | 2022-12-31 | $87.6M | $51.3M | +141.55% |
| 2021 | 2021-12-31 | $36.3M | $25.4M | +235.01% |
| 2020 | 2020-12-31 | $10.8M | — | — |
Xeris Biopharma Holdings quarterly gross profit
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $79.6M | $19.9M | +33.45% |
| Q1 2026 | 2026-03-31 | $72.6M | $21.2M | +41.18% |
| Q4 2025 | 2025-12-31 | $74.9M | $24.2M | +47.88% |
| Q3 2025 | 2025-09-30 | $63.4M | $22.7M | +55.83% |
| Q2 2025 | 2025-06-30 | $59.6M | $19.4M | +48.08% |
| Q1 2025 | 2025-03-31 | $51.4M | $16.7M | +48.24% |
| Q4 2024 | 2024-12-31 | $50.6M | — | — |
| Q3 2024 | 2024-09-30 | $40.7M | $556,000 | +1.39% |
| Q2 2024 | 2024-06-30 | $40.3M | $9.8M | +32.25% |
| Q1 2024 | 2024-03-31 | $34.7M | — | — |
| Q3 2023 | 2023-09-30 | $40.1M | $15.7M | +63.99% |
| Q2 2023 | 2023-06-30 | $30.5M | $10.0M | +48.58% |
| Q4 2022 | 2022-12-31 | $27.0M | $10.3M | +61.93% |
| Q3 2022 | 2022-09-30 | $24.5M | $16.6M | +212.05% |
| Q2 2022 | 2022-06-30 | $20.5M | $15.0M | +271.10% |
| Q1 2022 | 2022-03-31 | $15.6M | $9.4M | +151.20% |
| Q4 2021 | 2021-12-31 | $16.7M | — | — |
| Q3 2021 | 2021-09-30 | $7.8M | $1.2M | +18.50% |
| Q2 2021 | 2021-06-30 | $5.5M | — | — |
| Q1 2021 | 2021-03-31 | $6.2M | — | — |
| Q3 2020 | 2020-09-30 | $6.6M | — | — |
Xeris Biopharma Holdings gross profit trends
Over the last five fiscal years, Xeris Biopharma Holdings's gross profit increased from $10.8M to $249.3M, a change of $238.4M. The latest reported quarter, Q2 2026, shows $79.6M.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗